Ukraine's Farmak expects strong sales growth

18 December 2006

Ukrainian pharmaceutical producer Farmak says that it plans to increase its sales 79% by 2009, compared with last year's figure of 244.0 .0 million hryvni ($48.2 million), according to the Interfax news agency. The company's director general, Filya Zhebrovska, said that annual sales for 2006 will be up 18% on 2005, and for 2007 are forecast to grow an annual 26%-27%.

Farmak is currently undertaking a seven-year investment program worth 86.0 million euros ($114.6 million) that will see the upgrading of existing production facilities and the construction of a new one to Good Manufacturing Practice standards.

However, 4%-5% of this investment will be allocated for the promotion of new drugs, said Mr Zhebrovska. Next spring, the company will start building a new pharmaceutical plant that will make a variety of products including injectables. New production lines are to be launched at an existing facility in Kyiv.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight